This document announces a symposium on Mild Cognitive Impairment (MCI) that will provide 15 hours of continuing education credits for physicians and psychologists, featuring experts who will present on the causes, detection, and treatment of early dementia; it discloses any relationships between faculty and industry sponsors, and provides contact information for the symposium.
This document provides an agenda for the 10th Annual Symposium on Mild Cognitive Impairment and the 1st Early Alzheimer's Diagnostic Workshop being held January 14-15, 2012 in Miami Beach, Florida. The symposium and workshop will focus on advances in the clinical diagnosis and progression of Alzheimer's disease and related disorders, with an emphasis on the early stages of the disease. Over the two-day event, there will be keynote speeches and panel discussions on topics such as atypical presentations of Alzheimer's, the prion-like progression of the disease, and new concepts in pathogenesis. The goal is to help clinicians more accurately diagnose Alzheimer's and related conditions earlier.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from April 13-14, 2007 in Miami Beach, Florida. The symposium, directed by Dr. Ranjan Duara, will focus on developing earlier diagnosis of Alzheimer's disease and feature experts in fields related to dementia. Over two days, speakers will present on topics such as the pathology of aging and prodromal Alzheimer's, diagnosis of early Alzheimer's in clinical and research settings, and algorithms for integrating elements to achieve earlier diagnosis. The goal is to promote better understanding of diagnosing Alzheimer's disease earlier in its progression.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from March 7-8, 2008 in Miami Beach, Florida. The symposium will focus on disease modifying treatments for Alzheimer's disease. It will feature expert speakers discussing biomarkers for measuring progression and treatment effects in Alzheimer's, pathogenic mechanisms of cognitive impairment, non-pharmacological treatments, and potential disease-modifying pharmaceutical agents. The target audience is medical professionals in fields related to neurology and geriatrics. The symposium will provide updates on the latest research and allow for discussion on improving diagnosis and treatment of early-stage Alzheimer's.
This document provides information about the 8th Annual Symposium on Early Alzheimer's Disease that will take place on March 12-13, 2010 in Miami Beach, Florida. The symposium will focus on mild cognitive impairment and preclinical Alzheimer's disease, with sessions on interpreting psychometric test results, biomarkers for early detection, and results from longitudinal studies. National experts will present the latest research. The target audience is medical professionals working with dementia patients. Registration information is provided.
The document provides information about the 9th Annual Symposium on Mild Cognitive Impairment that will take place on April 29-30, 2011 in Miami Beach, Florida. It includes the agenda, list of distinguished faculty, registration information, and logistical details about the event. The symposium will focus on new criteria for prodromal and preclinical Alzheimer's disease, with sessions on risk factors, diagnosis and progression of mild cognitive impairment and preclinical Alzheimer's disease.
This document provides information about an upcoming symposium on Mild Cognitive Impairment (MCI). It will take place February 24-25, 2006 at the Eden Roc Resort & Spa in Miami Beach, Florida. The symposium is sponsored by several Alzheimer's research centers and will feature over 40 expert speakers. The goal is to provide the latest information on diagnosing and treating MCI, as well as discussing related topics like cognitive reserve, genetics, and vascular/medical factors. The symposium offers 15 hours of continuing education credits for physicians and psychologists.
This document provides information about the 7th Annual Mild Cognitive Impairment Symposium that will take place on March 27-28, 2009 in Miami, Florida. The symposium will focus on early Alzheimer's disease and non-Alzheimer's prodromal dementias. It will feature keynote speakers and breakout sessions on topics such as vascular cognitive impairment, prevention and treatment of mild cognitive impairment and early Alzheimer's, and distinguishing between early Lewy body disease and Alzheimer's disease. The document provides details on registration, continuing education credits, the agenda, faculty members, and objectives of the symposium.
This document summarizes the agenda and objectives for the 2nd Annual Mild Cognitive Impairment Symposium being held on February 27-28, 2004 in Miami Beach, Florida. The symposium consists of an educational module on day one and a research module on day two. Both modules will focus on understanding and detecting mild cognitive impairment, with objectives around diagnosis, subtypes, biomarkers, imaging, and screening tools. The symposium is sponsored by Mount Sinai Medical Center and aims to promote early detection and treatment of dementia.
This document provides an agenda for the 10th Annual Symposium on Mild Cognitive Impairment and the 1st Early Alzheimer's Diagnostic Workshop being held January 14-15, 2012 in Miami Beach, Florida. The symposium and workshop will focus on advances in the clinical diagnosis and progression of Alzheimer's disease and related disorders, with an emphasis on the early stages of the disease. Over the two-day event, there will be keynote speeches and panel discussions on topics such as atypical presentations of Alzheimer's, the prion-like progression of the disease, and new concepts in pathogenesis. The goal is to help clinicians more accurately diagnose Alzheimer's and related conditions earlier.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from April 13-14, 2007 in Miami Beach, Florida. The symposium, directed by Dr. Ranjan Duara, will focus on developing earlier diagnosis of Alzheimer's disease and feature experts in fields related to dementia. Over two days, speakers will present on topics such as the pathology of aging and prodromal Alzheimer's, diagnosis of early Alzheimer's in clinical and research settings, and algorithms for integrating elements to achieve earlier diagnosis. The goal is to promote better understanding of diagnosing Alzheimer's disease earlier in its progression.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from March 7-8, 2008 in Miami Beach, Florida. The symposium will focus on disease modifying treatments for Alzheimer's disease. It will feature expert speakers discussing biomarkers for measuring progression and treatment effects in Alzheimer's, pathogenic mechanisms of cognitive impairment, non-pharmacological treatments, and potential disease-modifying pharmaceutical agents. The target audience is medical professionals in fields related to neurology and geriatrics. The symposium will provide updates on the latest research and allow for discussion on improving diagnosis and treatment of early-stage Alzheimer's.
This document provides information about the 8th Annual Symposium on Early Alzheimer's Disease that will take place on March 12-13, 2010 in Miami Beach, Florida. The symposium will focus on mild cognitive impairment and preclinical Alzheimer's disease, with sessions on interpreting psychometric test results, biomarkers for early detection, and results from longitudinal studies. National experts will present the latest research. The target audience is medical professionals working with dementia patients. Registration information is provided.
The document provides information about the 9th Annual Symposium on Mild Cognitive Impairment that will take place on April 29-30, 2011 in Miami Beach, Florida. It includes the agenda, list of distinguished faculty, registration information, and logistical details about the event. The symposium will focus on new criteria for prodromal and preclinical Alzheimer's disease, with sessions on risk factors, diagnosis and progression of mild cognitive impairment and preclinical Alzheimer's disease.
This document provides information about an upcoming symposium on Mild Cognitive Impairment (MCI). It will take place February 24-25, 2006 at the Eden Roc Resort & Spa in Miami Beach, Florida. The symposium is sponsored by several Alzheimer's research centers and will feature over 40 expert speakers. The goal is to provide the latest information on diagnosing and treating MCI, as well as discussing related topics like cognitive reserve, genetics, and vascular/medical factors. The symposium offers 15 hours of continuing education credits for physicians and psychologists.
This document provides information about the 7th Annual Mild Cognitive Impairment Symposium that will take place on March 27-28, 2009 in Miami, Florida. The symposium will focus on early Alzheimer's disease and non-Alzheimer's prodromal dementias. It will feature keynote speakers and breakout sessions on topics such as vascular cognitive impairment, prevention and treatment of mild cognitive impairment and early Alzheimer's, and distinguishing between early Lewy body disease and Alzheimer's disease. The document provides details on registration, continuing education credits, the agenda, faculty members, and objectives of the symposium.
This document summarizes the agenda and objectives for the 2nd Annual Mild Cognitive Impairment Symposium being held on February 27-28, 2004 in Miami Beach, Florida. The symposium consists of an educational module on day one and a research module on day two. Both modules will focus on understanding and detecting mild cognitive impairment, with objectives around diagnosis, subtypes, biomarkers, imaging, and screening tools. The symposium is sponsored by Mount Sinai Medical Center and aims to promote early detection and treatment of dementia.
This curriculum vitae summarizes Jeffrey S. Gerdes' professional experience and education. It lists that he has been the chiropractor and clinical director of Carolina ChiroCare and Rehab Inc. in Raleigh, NC since 2010. It also notes that he received his doctorate of chiropractic from Palmer College of Chiropractic Florida in 2008. The CV provides details on his licensure, certifications, and extensive postgraduate education, including courses on MRI interpretation, neurological emergencies, and assessing medical fitness to return to work.
This document provides a curriculum vitae for Dr. Jeffrey S. Gerdes that includes his contact information, occupational history as a chiropractor since 2010, education including a Doctorate of Chiropractic from Palmer College of Chiropractic in 2008, licensure information, selected postgraduate education and certifications in areas related to chiropractic and neurology, and publications.
Washington State has a high rate of Alzheimer's disease deaths that is expected to increase 40% in the next 10 years. Many practices in the state lack guidelines for screening, diagnosing, and treating Alzheimer's and other dementias. The presentation discusses the Virginia Mason Cognitive Care in Primary Care program which provides resources and tools for a multidisciplinary approach to improve diagnosis, care, support, and planning for patients with cognitive issues. It also reviews diagnostic criteria and treatment approaches for vascular cognitive impairment, a common cause of dementia.
PELATIHAN PERAWATAN PALIATIF PADA STROKE - 16 maret 2020papahku123
This document discusses palliative care and end-of-life care for stroke patients. It outlines the seven principles of palliative care programs which focus on informed patient and family involvement, support for caregivers, a palliative approach to care, access to specialist palliative care, coordinated and integrated treatment, quality care from skilled staff, and community support. It also discusses assessing patient needs, managing symptoms, communication with patients and families, and the goals of palliative care for stroke which are to manage symptoms, provide counseling and support, and improve quality of life.
This document discusses end-of-life care considerations for patients with advanced dementia. It finds that feeding tubes do not prevent aspiration pneumonia or malnutrition in these patients and may in fact increase the risk of pressure ulcers and restraint use. Instead, oral assisted feeding is recommended to overcome eating difficulties. The benefits of discussing goals of care and treatment options are emphasized over defaulting to invasive interventions like feeding tubes that do not improve quality of life.
The document summarizes the experiences of students who participated in the 2010 MSTAR (Medical Student Training in Aging Research) Program Graduation. It provides short quotes from each student about how the program increased their interest in geriatrics and academic medicine. They observed various aspects of geriatric care and research. The students appreciated learning from the passionate faculty and seeing how geriatricians provide comprehensive, compassionate care for older patients.
This document discusses chronic disease management and the potential of preventive, predictive, and personalized (3P) medicine. It notes that chronic diseases are a leading cause of disability and healthcare costs. The 3P approach aims to detect diseases earlier through screening and biomarkers, enable targeted prevention, and develop personalized treatment plans. This could substantially improve quality of life while potentially reducing costs through earlier intervention and improved management of chronic conditions.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
This document provides an overview of advanced lung disease (ALD) and the role of hospice. It defines different types of ALD including obstructive and restrictive lung diseases. Signs and symptoms of ALD are discussed along with factors associated with poorer prognosis. Guidelines for hospice referral in ALD are reviewed. Trends showing increasing home and hospice deaths for those with lung disease are presented. Pharmacologic management of ALD focuses on symptom control rather than disease modification.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
The document provides information about continuing education (CE) credit approval for various healthcare professionals through different VITAS Healthcare programs. It lists the states and professional groups that various VITAS programs are approved to provide CE credits for, including nurses, social workers, nursing home administrators, and respiratory therapists. It also provides the approval numbers and organizations. The document contains multiple sections that continue listing the state-by-state and professional group CE credit approval information for VITAS Healthcare programs.
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
The document discusses the career path and experiences of a family physician. It describes their journey from high school through medical school and residency training. As a family physician, they provide comprehensive primary care to patients of all ages, conduct a wide range of medical procedures, and value building long-term relationships with patients to support their overall health and well-being.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
“Neurologic deficits
are frequently seen
in patients with
stroke. One of this is
a motor deficit
which is the
weakness of the
body. Another one is
an emotional deficit
which is
depression.”
Patient X has
decreased appetite
before
hospitalization
because of
depression due to
his condition. But
now he is willing to
eat during
hospitalization
because of proper
Page 7 of 38
pagkain...”
2. Hygiene
Daughter
verbalized:
“Hindi na siya
makapag-ayos
ng sarili...”
Needs minimal
assistance in
bathing and
g
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
This document provides information about the 20th Annual Primary Care in Paradise conference taking place from March 23-26, 2015 in Maui, Hawaii. The conference is designed by primary care physicians for primary care physicians to present content on commonly encountered medical specialties and therapeutic areas from a primary care perspective. Over the four days, physicians will receive lectures and case studies on topics like gastroenterology, neurology, pulmonary embolism, and more to help them better diagnose, treat and manage patients. The goal is for primary care doctors to leave with practical skills and resources to apply in their own practices.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course provided an overview of new developments in diagnosing and treating kidney cancer.
This curriculum vitae summarizes Jeffrey S. Gerdes' professional experience and education. It lists that he has been the chiropractor and clinical director of Carolina ChiroCare and Rehab Inc. in Raleigh, NC since 2010. It also notes that he received his doctorate of chiropractic from Palmer College of Chiropractic Florida in 2008. The CV provides details on his licensure, certifications, and extensive postgraduate education, including courses on MRI interpretation, neurological emergencies, and assessing medical fitness to return to work.
This document provides a curriculum vitae for Dr. Jeffrey S. Gerdes that includes his contact information, occupational history as a chiropractor since 2010, education including a Doctorate of Chiropractic from Palmer College of Chiropractic in 2008, licensure information, selected postgraduate education and certifications in areas related to chiropractic and neurology, and publications.
Washington State has a high rate of Alzheimer's disease deaths that is expected to increase 40% in the next 10 years. Many practices in the state lack guidelines for screening, diagnosing, and treating Alzheimer's and other dementias. The presentation discusses the Virginia Mason Cognitive Care in Primary Care program which provides resources and tools for a multidisciplinary approach to improve diagnosis, care, support, and planning for patients with cognitive issues. It also reviews diagnostic criteria and treatment approaches for vascular cognitive impairment, a common cause of dementia.
PELATIHAN PERAWATAN PALIATIF PADA STROKE - 16 maret 2020papahku123
This document discusses palliative care and end-of-life care for stroke patients. It outlines the seven principles of palliative care programs which focus on informed patient and family involvement, support for caregivers, a palliative approach to care, access to specialist palliative care, coordinated and integrated treatment, quality care from skilled staff, and community support. It also discusses assessing patient needs, managing symptoms, communication with patients and families, and the goals of palliative care for stroke which are to manage symptoms, provide counseling and support, and improve quality of life.
This document discusses end-of-life care considerations for patients with advanced dementia. It finds that feeding tubes do not prevent aspiration pneumonia or malnutrition in these patients and may in fact increase the risk of pressure ulcers and restraint use. Instead, oral assisted feeding is recommended to overcome eating difficulties. The benefits of discussing goals of care and treatment options are emphasized over defaulting to invasive interventions like feeding tubes that do not improve quality of life.
The document summarizes the experiences of students who participated in the 2010 MSTAR (Medical Student Training in Aging Research) Program Graduation. It provides short quotes from each student about how the program increased their interest in geriatrics and academic medicine. They observed various aspects of geriatric care and research. The students appreciated learning from the passionate faculty and seeing how geriatricians provide comprehensive, compassionate care for older patients.
This document discusses chronic disease management and the potential of preventive, predictive, and personalized (3P) medicine. It notes that chronic diseases are a leading cause of disability and healthcare costs. The 3P approach aims to detect diseases earlier through screening and biomarkers, enable targeted prevention, and develop personalized treatment plans. This could substantially improve quality of life while potentially reducing costs through earlier intervention and improved management of chronic conditions.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
This document provides an overview of advanced lung disease (ALD) and the role of hospice. It defines different types of ALD including obstructive and restrictive lung diseases. Signs and symptoms of ALD are discussed along with factors associated with poorer prognosis. Guidelines for hospice referral in ALD are reviewed. Trends showing increasing home and hospice deaths for those with lung disease are presented. Pharmacologic management of ALD focuses on symptom control rather than disease modification.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
The document provides information about continuing education (CE) credit approval for various healthcare professionals through different VITAS Healthcare programs. It lists the states and professional groups that various VITAS programs are approved to provide CE credits for, including nurses, social workers, nursing home administrators, and respiratory therapists. It also provides the approval numbers and organizations. The document contains multiple sections that continue listing the state-by-state and professional group CE credit approval information for VITAS Healthcare programs.
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
The document discusses the career path and experiences of a family physician. It describes their journey from high school through medical school and residency training. As a family physician, they provide comprehensive primary care to patients of all ages, conduct a wide range of medical procedures, and value building long-term relationships with patients to support their overall health and well-being.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
“Neurologic deficits
are frequently seen
in patients with
stroke. One of this is
a motor deficit
which is the
weakness of the
body. Another one is
an emotional deficit
which is
depression.”
Patient X has
decreased appetite
before
hospitalization
because of
depression due to
his condition. But
now he is willing to
eat during
hospitalization
because of proper
Page 7 of 38
pagkain...”
2. Hygiene
Daughter
verbalized:
“Hindi na siya
makapag-ayos
ng sarili...”
Needs minimal
assistance in
bathing and
g
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
This document provides information about the 20th Annual Primary Care in Paradise conference taking place from March 23-26, 2015 in Maui, Hawaii. The conference is designed by primary care physicians for primary care physicians to present content on commonly encountered medical specialties and therapeutic areas from a primary care perspective. Over the four days, physicians will receive lectures and case studies on topics like gastroenterology, neurology, pulmonary embolism, and more to help them better diagnose, treat and manage patients. The goal is for primary care doctors to leave with practical skills and resources to apply in their own practices.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course provided an overview of new developments in diagnosing and treating kidney cancer.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course aimed to provide the latest information on diagnosing and treating kidney cancer to practicing urologists.
A New Perspective On Survival Outcomes In Multiple SclerosisJustin Knight
This document discusses new findings on survival outcomes in multiple sclerosis (MS) from international registries and databases. It summarizes that MS patients have a mean decrease in survival time of 6 to 12 years compared to the general population. A 21-year follow-up study of interferon beta-1b treatment showed that early treatment may positively impact long-term mortality rates in MS patients compared to delayed treatment. The findings suggest that early and continued disease-modifying treatment may improve long-term survival outcomes for individuals with MS.
This document summarizes key points from a presentation on establishing survivorship programs. It discusses the need for navigation and survivorship care due to issues cancer survivors face. New CoC standards require navigation programs, survivorship care plans, and distress screening. A multi-disciplinary survivorship clinic example integrates navigation, medical, mental health and lifestyle support for survivors. Barriers include financial sustainability and changing provider mindsets. Success comes from collaboration, tailored care, and improving survivor well-being and care coordination.
This study aimed to assess the knowledge of cardiac patients regarding complications and lifestyle modifications. A quantitative approach with a descriptive research design was used. 30 cardiac patients attending a hospital cardiology OPD in Nellore, India were sampled. Data was collected using a questionnaire and analyzed using descriptive and inferential statistics. The results found moderate knowledge among patients. There was a significant association between knowledge and food habits. The study concluded there is a need for interventions to improve patient knowledge on cardiac complications and lifestyle changes.
Annals of Behavioral Medicine Volume 49-Issue 1 Supplement-April 2015Monique Tsang, BS, CNA
This seminar provides an overview of a pilot bibliotherapy program for survivors of acquired brain injury (ABI) and individuals with chronic pain or disability. The program was started in 2012 at Erie County Medical Center in Buffalo, NY and has shown benefits to quality of life and symptom reduction. The seminar will present qualitative data on the impact of the program and provide details on its development, mission statement, recruitment process, book selection, and collaboration with rehabilitation and behavioral health services. Bibliotherapy shows potential as a cost-effective and sustainable treatment approach to target common deficits after ABI or injury such as reduced empathy, poor perspective taking, and impaired information processing.
Annals of behavioral medicine volume 49 issue 1 supplement april 2015Monique Tsang, BS, CNA
The current study investigated whether a single presentation on sleep hygiene could result in improvement in reported sleep quality and quantity for undergraduate students newly entering university.
Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Con...Nutricia
This document summarizes the conclusions of an expert panel convened by the International Association of Gerontology and Geriatrics to discuss early detection of cognitive impairment. The panel agreed that:
1) Validated screening tests that take 3 to 7 minutes can identify early cognitive impairment.
2) The most effective approach is to use both patient-reported and informant-reported screening tools.
3) Early cognitive impairment may have treatable components, and emerging evidence supports interventions like medical treatment, nutrition changes, and physical/cognitive exercise to delay or reduce decline.
Discussion post reply APA Format2 references for each discussiLyndonPelletier761
This discussion post reply summarizes steps taken at Sacred Heart Hospital to reduce specimen mislabeling errors through the use of an electronic positive patient identification (EPPID) system called Collection Manager. The post discusses how previously Sacred Heart used pre-printed labels that could result in errors, but now uses Collection Manager which prints labels at the patient's bedside after their armband is scanned. This eliminates manual writing and pre-printed labels, reducing errors. The post provides examples of how Collection Manager integrates with the laboratory information system to ensure accurate labeling. It is reported that Sacred Heart saw a reduction in mislabeling errors from about 10 per year to only 1 error per year after implementing Collection Manager.
Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics ( PDFDrive...InsSilva801685
This document provides a table of contents for the book "Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics". The table of contents lists 50 chapters organized into 6 parts that cover topics such as principles of laboratory medicine, analytical techniques and instrumentation, analytes, pathophysiology, molecular diagnostics, and reference information.
Mayo Clinic - 2011 ACC Satellite Education Symposiumswest0521
This is satellite educational symposium during the 2011 ACC Scientific Session. The program would be of interest for imaging professionals, cardiologists, radiologists, nuclear cardiology and nuclear medicine specialists and other healthcare providers interested in the application of cardiac imaging in clinical practice.
The document discusses the Hereditary Neuropathy Foundation's (HNF) efforts to accelerate research for treatments for Charcot-Marie-Tooth (CMT) disease and related inherited neuropathies. Some key points:
- HNF submitted a large proposal to the NIH for $1.25M per year over 5 years to fund clinical trials and research to help translate existing preclinical research into therapies more quickly.
- Currently there are no effective treatments for CMT despite the discovery of the causal genes over 20 years ago. HNF's TRIAD program aims to increase collaboration between advocacy groups, academia, and industry to speed development of therapies.
- HNF is conducting studies to develop better
Transforming Medicine Through Personalized Health Care at Ohio State Universi...Ryan Squire
The document describes Ohio State University Medical Center's vision to transform medicine through personalized health care. Their goal is to move from today's reactive, disease-based system to a proactive, wellness-based system using systems biology tools. They plan to create predictive, personalized, precise and preventive (P4) medicine through discovery platforms using omics data, modeling, and imaging. These platforms will be translated through diagnostics, devices, and targeted therapeutics. Applications include pilot programs, a personalized medicine collaborative, and accountable care organizations. The overall vision is to improve quality and lower costs through disruptive innovation and personalized strategic health plans.
This document provides an overview and learning objectives for an issue of Continuum: Lifelong Learning in Neurology focused on spinal cord disorders. The issue aims to help neurologists stay up-to-date in their knowledge and skills for defining spinal cord syndromes, interpreting MRI findings, recognizing common spinal cord disorders, and managing related complications. Specific topics covered include cervical spondylosis, vascular disorders, infections, autoimmune conditions, neoplasms, and cauda equina syndrome.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Seventh Annual Next Generation Dx SummitJaime Hodges
The Next Generation Dx Summit (www.nextgenerationdx.com), entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
This document provides information about the "BioData World West 2017" conference taking place April 26-27, 2017 in San Francisco. The conference will bring together over 200 participants from various backgrounds to discuss disruptive approaches in drug development, personalized medicine, and clinical applications using big data in precision medicine. Expert speakers will present on topics including genomics, precision medicine, and a new AI track in partnership with Merck. Registering online reserves a place at the conference and featured sessions will explore various applications and challenges of harnessing big data in healthcare and biomedicine.
The AIHM Annual Conference will take place from October 29th to November 4th at the Paradise Point Hotel in San Diego, CA. Over 800 health professionals are expected to attend for advanced lectures, workshops, and networking opportunities focused on integrative health and medicine. Some conference highlights include tracks on integrative cardiology, manual medicine, and a keynote from Deepak Chopra on science and social impact. Attendees will learn how to effectively incorporate integrative practices like therapeutic massage and osteopathic techniques into patient care. The conference aims to bring global practitioners together to advance integrative health as an accessible standard of care.
The document announces a continuing medical education event at the University of South Alabama on Wegener's granulomatosis presented by Dr. Mario Magnone. The event objectives are to understand the pathogenesis, organ involvement, distinguishing factors, and treatment options for Wegener's granulomatosis. It is intended to increase physician knowledge and improve patient outcomes. The event offers 1 AMA PRA Category 1 Credit for participating physicians.
Robin Murray commentary during the SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia is not a single disease but rather two different syndromes according to the DSM-5 and ICD-10 diagnostic criteria, with only 70% of patients meeting criteria for both. This raises questions about what to call patients who meet one but not the other and how useful the term "schizophrenia" is given the lack of biological markers and different interpretations by psychiatrists. Looking at dimensions of psychosis symptoms, predominant causes, and severity/persistence may provide more helpful information to patients and their outcomes than the term schizophrenia.
Eske Derks commentary - SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia patients are qualitatively different from their healthy siblings and controls based on genetic studies. While there is some genetic overlap between schizophrenia, psychosis, and general mental health risk, distinct genetic factors for schizophrenia have also been found. Specifically, over 200 genetic risk factors for schizophrenia have been identified. Based on these genetic findings, the presenter concludes that schizophrenia is not simply an extreme on a normal distribution of traits and replacing it with a psychosis spectrum disorder would be premature.
Jim van Os presentation during SRF live webinar "Is Schizophrenia Dead Yet?"wef
This document discusses the debate around schizophrenia diagnoses and proposes an alternative psychosis spectrum syndrome approach. It summarizes that the debate is about clinical diagnosis, not research criteria. It also notes that around 3.5% of people experience some form of psychosis, but the current system publishes overwhelmingly on only one category, schizophrenia. The document advocates for recognizing a spectrum approach and dimensional personal diagnoses within a categorical psychosis spectrum to better reflect individuals' experiences and needs.
Rene Kahn commentary during SRF Live Webinar: "Is Schizophrenia Dead Yet?wef
Schizophrenia and bipolar disorder are distinct conditions with little genetic overlap and different risk factors. Schizophrenia is primarily a cognitive disorder, not defined by psychosis, as cognitive decline precedes psychotic episodes. While some wish to deny the poor prognosis of schizophrenia, studies show the disorder leads to reduced life expectancy, high suicide and unemployment rates, and long-term functional impairment for most patients.
NIMH i PSC Assays for the Drug Pipeline - Panchisionwef
Dr David Panchision's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
Schizophrenia Research Forum Live Webinar - June 28, 2017 - Rusty Gage wef
1) The document describes a study using induced pluripotent stem cells (iPSCs) derived from bipolar disorder (BD) patients to model the disease in vitro.
2) Hippocampal dentate gyrus-like neurons were differentiated from iPSCs and showed hyper-excitability at both the molecular and functional levels in BD-derived neurons.
3) Treatment with lithium rescued the hyper-excitability phenotype in neurons derived from lithium-responsive BD patients but not lithium non-responsive patients, suggesting patient-specific responses.
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
Kristen Brennand presentation at the live webinar of June 28, 2017 hosted by the Schizophrenia Research Forum (http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models)
STRATEGIES FOR COMMUNICATION AND SENSITIVITY FOR PERSONS EXPERIENCING DEMENTI...wef
This document summarizes a workshop on strategies for communicating with persons experiencing dementia. It discusses how communication is impacted at different stages of dementia from early to late stage. In early stage, word retrieval becomes difficult. In middle stage, language abilities further decline making conversation challenging. In late stage, communication is limited but sensory stimulation through touch, sound, and smell can still connect a person. The workshop provides guidance on adapting approaches to best communicate with someone based on their stage of dementia.
Translating from Animal Models to Human Schizophrenia - Insights into Pathoph...wef
Presentation made by Dr. Tony Grace at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Presentation made by Dr. Oliver Howes at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Topography and functional significance of the dopaminesgic dysfunction in sch...wef
Presentation made by Dr. Anissa Abi-Dargham at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
SRF Webinar - What It Will Take to Make Coordinated Specialty Care Available ...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
SRF Webinar: Beyond DUP - Addressing Disengagement in Community-based Early I...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
This document provides an overview of memory loss, dementia, and Alzheimer's disease. It defines key terms, describes symptoms at different stages of dementia, and discusses a person-centered approach to care. The main points are:
1) Dementia is not a specific disease but a general term for symptoms caused by various brain disorders, while Alzheimer's disease is the most common cause of progressive dementia.
2) Early stage dementia symptoms include memory loss, impaired judgment, and difficulty completing tasks, while middle and late stage symptoms involve greater impairment and dependence on others for care.
3) A person-centered approach focuses on maintaining an individual's dignity, independence, and identity through techniques like validation, respect, and personalized
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
HEAR approach to behavior management Live webinar Feb 1 2017wef
Slides presented at the HEAR Approach to Behavior Management live webinar of February 1, 2017, featuring presentations from Dr. Andrew Heck and Carol Garby.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
1. ACCREDITATION
Mount Sinai Medical Center is
accredited by the Accreditation
Council for Continuing Medical
Education (ACCME) to sponsor
continuing medical education for
physicians. Mount Sinai designates
this continuing medical educational
activity for a maximum of 15
Category 1 credits toward the
American Medical Association
Physician’s Recognition Award
(AMA). Each physician should claim
only those hours of credit that he/she
actually spent in the educational
activity.
CEU ACCREDITATION
A total of 15 Continuing Education
credits for Psychologists will be
offered through MAGEC (Miami Area
Geriatric Education Center)
3 R D A N N U A L
Mild Cognitive Impairment
(MCI) Symposium
PRESENTED BY:
The Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach, Florida
and
The Johnnie B. Byrd, Sr. Alzheimer’s Center & Research Institute
Tampa, Florida
Friday - Saturday
March 11-12,2005
SYMPOSIUM LOCATION:
Sheraton Bal Harbour Beach Resort
9701 Collins Ave., Bal Harbour, FL 33154
PROGRAM DIRECTOR
Ranjan Duara, MD
Medical Director
Wien Center for Alzheimer’s Disease & Memory Disorders
Mount Sinai Medical Center, Miami Beach, FL
Departments of Medicine and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
SPONSORED BY:
THE BEHRMAN CENTER FOR MEDICAL EDUCATION
AT MOUNT SINAI MEDICAL CENTER
An accredited interactive Symposium offering
15 hours of Category 1 credits for Physicians
and 15 CEU accreditation hours for Psychologists offered through MAGEC.
Mild Cognitive
Impairment (MCI)
Symposium
For information, please contact:
Warren Barker
Phone: 305-674-2592
Email: mcisymposium@msmc.com
3 R D A N N U A L
Mild Cognitive
Impairment (MCI)
Symposium
4300 Alton Road, Miami Beach, FL 33140
3 R D A N N U A L
Mild Cognitive Impairment
(MCI) Symposium
DISCLOSURE STATEMENT
Mount Sinai Medical Center in accordance with the Standards for Commercial
Support of the Accreditation Council for Continuing Medical Education
(ACCME) will disclose the existence of any significant financial interest or other
relationship between a faculty member or a sponsor has (1) with the
manufacturer(s) of any commercial product(s) and/or provider(s) of
commercial services discussed in the educational presentation and (2) with any
commercial supporters of the activity. Faculty is also required to disclose to the
audience, during their presentation, any investigational/unlabeled use that is
discussed. Information concerning Faculty relationship with industry will be
disclosed and available on the Symposium Syllabus and on meeting site.
CORPORATE SUPPORT
This symposium is made possible by unrestricted educational grants from
pharmaceuticals companies; our appreciation is expressed for their support of
this program. Sponsors will be listed on our Symposium Syllabus.
SYMPOSIUM INFORMATION
Please contact: Warren Barker
MCI Symposium Coordinator
Wien Center for Alzheimer’s Disease & Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 - Fax: 305-674-2996
E-mail: mcisymposium@msmc.com
2. NEEDS ASSESSMENT
Continuing success in the development of
new treatments and preventive measures for
Alzheimer’s disease and other causes of
dementia have prompted the need for a
better recognition of the earliest stages of
these conditions. The purpose of this
symposium is to provide a forum where new
information can be provided and in-depth
discussions can take place about Mild
Cognitive Impairment and all its subtypes.
This will be accomplished via a keynote
lecture and five mini-symposia. The
symposium will feature a panel of national
and international experts in the fields of
neurology, psychiatry, geriatrics,
neuropsychology, brain imaging and
epidemiology. These experts will present
updates on the causes and early detection of
incipient dementias, and their prevention
and treatment. Each mini-symposium will be
followed by an extended discussion period,
allowing active audience participation to
enhance the learning process.
TARGET AUDIENCE
This activity is designed for:
– Neurologists
– Psychiatrists
– Geriatricians
– Radiologists (neuroimaging specialists)
– Epidemiologists
– Neuropsychologists
– Neuroscientists
Richard Mayeux, MD, MSc
(Keynote Speaker)
Gertrude H. Sergievky Professor of Neurology,
Psychiatry and Epidemiology
Columbia University Medical Center
New York, NY
David A. Bennett, MD
Director, Rush Alzheimer’s Disease Center
Rush University Medical Center
Chicago, IL
Carol Brayne, MD
Professor of Public Health Medicine
Cambridge University
Cambridge, UK
Jody Corey-Bloom, MD, PhD
Professor of Neurosciences
University of California, San Diego School of
Medicine
San Diego, CA
Herman Buschke, MD
Professor of Neurology and Neuroscience
Albert Einstein College of Medicine
Bronx, NY
Steven DeKosky, MD
Professor and Chairman of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, PA
Mony John DeLeon, EdD
Professor of Psychiatry
New York University School of Medicine
New York, NY
Robert Friedland, MD
Professor of Neurology
Case Western Reserve University
Cleveland, OH
Mary Ganguli, MD, MPH
Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, PA
Lawrence Honig, MD, PhD
Associate Professor of Clinical Neurology
Columbia University College of Physicians &
Surgeons
New York, NY
Gregory Jicha, MD
Assistant Professor of Neurology
Mayo Medical School, Rochester
Rochester, MN
Julene K. Johnson, PhD
Assistant Professor of Neurology
University of California, San Francisco
San Francisco, CA
Keith A. Johnson, MD
Assistant Professor; Radiologist and
Associate Neurologist
Harvard Medical School
Cambridge, MA
Jeffrey Kaye, MD
Professor of Neurology and Biomedical
Engineering
Oregon Health and Science University
Portland, OR
William Klunk, MD, PhD
Associate Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, PA
Oscar Lopez, MD
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, PA
David A. Loewenstein, PhD,
ABPP/ABCN
Director, Psychological Services &
Neuropsychology Lab
Wien Center, Mount Sinai Medical Center
University of Miami School of Medicine
Miami, FL
Jennifer Manly, PhD
Assistant Professor of Neuropsychology
Columbia University Medical Center
New York, NY
Ian McKeith, MD
Professor of Old Age Psychiatry
University of Newcastle upon Tyne
United Kingdom
John Morris, MD
Friedman Distinguished Professor of
Neurology
Washington University School of Medicine
St. Louis, MO
Ronald Petersen, MD, PhD
Director, Mayo Alzheimer’s Disease Center
Mayo Medical School, Rochester
Rochester, MN
Donald Royall, MD
Associate Professor of Psychiatry, Medicine,
and Clinical Pharmacology
University of Texas Health Science Center
San Antonio, TX
Norman Relkin, MD, PhD
Associate Professor of Clinical Neurology &
Neuroscience
Weill Medical College of Cornell
New York, NY
Stephen Salloway, MD, MS
Professor of Clinical Neurosciences and
Psychiatry
Brown Medical School
Providence, RI
Philip Scheltens, MD, PhD
Professor of Cognitive Neurology
Vrije Universiteit Medical Center
Amsterdam, Netherlands
David Snowdon, PhD
Director, The Nun Study University of Kentucky
Saunders-Brown Center on Aging
Lexington, KY
Reisa Sperling, MD, MSc
Assistant Professor of Neurology
Harvard Medical School
Cambridge, MA
Mary Tierney, PhD
Professor of Family and Community Medicine
University of Toronto
Toronto, Canada
Frederick Unverzagt, PhD
Associate Professor of Psychiatry
Indiana University School of Medicine
Indianapolis, IN
Joe Verghese, MD, MS
Assistant Professor of Neurology
Albert Einstein College of Medicine
New York, NY
Kathleen A. Welsh-Bohmer, PhD,
ABPP/ABCN
Professor of Psychiatry and Behavioral Sciences
Duke University Medical Center
Durham, NC
Lon White, MD, MPH
Professor of Medicine
University of Hawaii
Honolulu, HI
Robert S. Wilson, PhD
Professor of Neurological Sciences and
Psychology
Rush University Medical Center
Chicago, IL
EDUCATIONAL OBJECTIVES
The overall purpose of the symposium is to promote a better
understanding and earlier diagnosis of mild cognitive impairment
(MCI) and incipient dementia. Upon completion of this symposium,
the attendees should have a better understanding of the following:
1. Etiological Subtypes of MCI
a. Clinical features of etiological subtypes of MCI
b. Rates of progression in etiological subtypes of MCI
c. Current limitations in diagnosing etiological subtypes of MCI
2. Neuropathology of MCI
a. The frequency of occurrence of degenerative and vascular
pathology in elderly subjects with normal cognition and MCI
b. The correlation of regional brain pathology and brain
atrophy to cognitive performance in MCI
c. The correlation of neuropathology to clinical features and
rates of progression in MCI
3. Neuroimaging in MCI
a. Quantitative volumetric and visual rating of brain images
(MRI, PET, and SPECT) in elderly with normal cognition,
MCI, and AD
b. Neuroimaging techniques that have demonstrated the ability
to predict future clinical course in normal, MCI, and AD
subjects
c. Amyloid imaging in MCI
d. The added value of brain imaging to a clinical diagnosis of
MCI subtype
4. Longitudinal Assessment in MCI
a. Patterns of progression in subjects diagnosed with MCI
b. Cognitive tests that are useful in measuring longitudinal
changes in MCI subjects
c. The utility of functional measures in longitudinal studies of
MCI
d. Rates of progression of subtypes of MCI in longitudinal aging
studies
5. Prevention and Treatment of MCI
a. The effect of treatment with cholinesterase inhibitors in
subjects with MCI
b. Lifestyle factors that may delay the onset of MCI
c. The effect of cognitive stimulation and rehabilitation in MCI
DISTINGUISHED GUEST FACULTY
Program Director
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer’s Disease & Memory Disorders
Mount Sinai Medical Center, Miami Beach, FL
Miller School of Medicine, University of Miami
3. PM
1:00-2:45 Mini-Symposium: Neuropathology of MCI
Chair: John Morris, MD
– Overview and Washington University
Series
John Morris, MD
– Mayo Clinic Series
Gregory Jicha, MD
– Rush Memory and Aging Study
David Bennett, MD
– Aging with Grace: Findings from the
Nun Study Series
David Snowdon, PhD
– MRC-CFAS Series
Carol Brayne, MD
– Honolulu-Asia Aging Study
Lon White, MD, MPH
– Neocortical vs Medial Temporal
Pathology in MCI
Jody Corey-Bloom, MD, PhD
– Neurochemistry of MCI
Steven DeKosky, MD
2:45-3:45 Open Discussion and Summary
3:45-5:15 Mini-Symposium: Neuroimaging in MCI
Chair: Mony DeLeon, EdD
– Structural MRI- Normal Aging to MCI
Jeffrey Kaye, MD
– Visual Rating of Atrophy of MTL
Philip Scheltens, MD, PhD
– MRI and Biomarkers in MCI
Mony DeLeon, EdD
– Functional MRI Studies of Memory
in MCI
Reisa Sperling, MD, MSc
– Perfusion MRI
Oscar Lopez, MD
– SPECT and PET in MCI
Keith Johnson, MD
– Amyloid Imaging and MCI
William Klunk, MD
5:15-6:00 Open Discussion and Summary
6:00 Adjourn
7:00-9:00 Welcome Dinner
AM
7:30-8:00 Breakfast Buffet
8:00-8:15 Opening Remarks
Ranjan Duara, MD
8:15-10:15 Mini-Symposium on Longitudinal
Assessment in MCI
Chair: David Loewenstein, PhD
– Assessment of Change in Cognition
in MCI
David Loewenstein, PhD
– MCI as a Dementing Process
Donald Royall, MD
– Cache County Memory Study
Kathleen Welsh-Bohmer, PhD
– Canadian Study of Health and
Aging
Mary Tierney, PhD
– Indianapolis-Ibadan Study
Frederick Unverzagt, PhD
– MCI Among Ethnically Diverse
Elders
Jennifer Manly, PhD
– Mild Cognitive Impairment in Old
Age
Robert Wilson, PhD
– Modeling Memory Decline in Older
Adults
Herman Buschke, MD
10:15-11:30 Open Discussion and Summary
11:30-1:00 LUNCH BREAK
PM
1:00-3:00 Mini-Symposium on Prevention and
Treatment of MCI
Chair: Ronald Petersen, MD, PhD
– Treatment Studies with Donepezil
Ronald Petersen, MD, PhD
– Key Lessons Learned from the 24-week
Donepezil Trial for MCI
Stephen Salloway, MD
– Cognitive Rehabilitation in MCI and Mild
Dementia
David Loewenstein, PhD
– Cognitive and Recreational Activities for
Preventing MCI
Joe Verghese, MD
– Diet, Mental and Physical Activities for
Preventing MCI
Robert Friedland, MD
– Chronic Psychological Distress and
Cognitive Impairment in Old Age
Robert Wilson, PhD
3:00 -4:00 Open Discussion and Summary
4:00 Adjourn
Friday, March 11,2005 Saturday, March 12, 2005
AM
7:30-8:00 Breakfast Buffet
8:00-8:15 Welcome and Introduction
Ranjan Duara MD
8:15-9:15 Mild Cognitive Impairment: Risk
Factors, Etiology and Biomarkers
Richard Mayeux, M.D., M.Sc. -
Keynote Speaker
9:15-10:30 Mini-Symposium: MCI Etiological
Subtypes
Chair: Steven DeKosky, MD
– Overview and MCI-AD
Ronald Petersen, MD, PhD
– MCI-Vascular/Leukomalacia
Lawrence Honig, MD, PhD
– MCI Lewy Body Disease
Ian McKeith, MD
– MCI-Fronto-Temporal Dementia
Julene Johnson, PhD
– MCI-Normal Pressure Hydrocephalus
Norman Relkin, MD, PhD
– MCI-None of the Above
Mary Ganguli, MD, MPH
10:30-11:30 Open Discussion and Summary
11:30-1:00 LUNCH BREAK
4. REGISTRATION FORM
THREE EASY WAYS TO REGISTER:
ON LINE FAX US MAIL US
www.byrdinstitute.org/MCISymposium Attn: Warren Barker Warren Barker
Fax to (305) 674-2996 Wien Center
4300 Alton Road
Miami Beach, FL 33140
REGISTRANT INFORMATION Please print:
_____________________________________________________________________________________________
LAST NAME FIRST NAME MI
DEGREE: MD DO Ph.D OTHER __________________________________________________
_____________________________________________________________________________________________
ADDRESS
_____________________________________________________________________________________________
CITY STATE ZIP CODE COUNTRY
_____________________________________________________________________________________________
E-MAIL FAX TELEPHONE
REGISTRATION FEES:
Physicians: Discounted: $280.00 (if registered by February 18)
$300.00 (if registered after February 18)
$325.00 on site registration
Non-Physicians: Discounted: $225.00 (if registered by February 18)
$250.00 (if registered after February 18)
$275.00 on site registration
$150.00 (students and nurses)
PAYMENT METHOD:
American Express Master Card Visa Check in the amount of _____________________
Card No. ________________________________________________ Expiration Date ______ / ________
Cardholder’s Name _____________________________________________________________________
Signature _____________________________________________________________________________
Payment must accompany registration form
METHOD OF REGISTRATION
To register by mail or fax: please complete
the registration form and send it with the
payment method to the above mailing
address or fax number.
To register by email: provide the
information requested on the registration
form in an e-mail message and send to:
mcisymposium@msmc.com
Registration confirmations will be issued.
Payment: Registration fees can be sent by
credit card or check, no cash is accepted.
Please make all checks payable to MCI
SYMPOSIUM, MSMC.
Registration Fee Inclusions: Registration fees
include admittance to all the scientific
conferences, conference materials, validated
parking, breakfast, lunch, refreshment
breaks, welcome dinner as specified in the
program.
Registration Hours: The conference
registration desk will be staffed:
Friday, March 11 -
Meeting Room: Caribbean Ballroom
7:30 am - 6:00 pm.
Lunch: Sundeck
12:00 pm - 1:00 pm
Welcome Dinner:
Beach House
7:00 pm - 10.00 pm
Saturday, March 12 -
Meeting Room: Caribbean Ballroom
7:30 am.- 4:00 pm.
Lunch:
Crystal Ballroom 1
12:00 pm - 1:00 pm
Refund Policy: Full refund will be given if written
notice is received not later than February 15, 2005.
All refunds will be processed after the meeting.
R E G I S T R A T I O N I N F O R M A T I O N
SYMPOSIUM LOCATION
SHERATON BAL HARBOUR BEACH RESORT
9701 Collins Avenue, Bal Harbour, FL 33154
Phone: 1-888-627-7079 • Fax: 1-305-864-2601
Nestled on ten acres of tropical gardens and sandy beaches, the
Sheraton Bal Harbour Beach Resort is midway between Miami Beach
and Ft. Lauderdale. This deluxe,
four-diamond resort features a
combination of Latin flair and
small town charm and is ideal for
both romantic getaways and
family vacations.
All 645 guest rooms and suites
include Sheraton Sweet
Sleeper(SM) beds, and pool, ocean,
or village views. Services include a spa,
fitness center, Kid’s Club, and lagoon-
style pool featuring Jacuzzis and a
waterslide. Over 50,000 square feet of
flexible meeting and event facilities
offer High Speed Internet Access and are ideal for both business and
social functions.
Directly across the street are the famous Bal Harbour Shops,
a unique collection of internationally renowned boutiques, shops,
and cafes set in beautiful tropical gardens. The world-famous
South Beach Art Deco District and Lincoln Road are also just
minutes away.
HOTEL RESERVATIONS
For the convenience of the 3rd
MCI Symposium attendees a
limited number of rooms have
been reserved at the special daily
rate of $290.00 (single or double
occupancy, plus resort fees, state
and local taxes). To receive this
special rate, reservations must be
made directly with the Sheraton
Bal Harbour Beach Resort and you must mention that you are a
registrant of the 3rd Annual MCI Symposium. Rooms will be held at
the special rate until Tuesday, February 15, 2005. Rooms at the
discounted rate will be allocated on a first-come, first-served basis.
Reservations received after the cut-off date is subject to availability
and prevailing rates.
FOR ROOM RESERVATIONS CALL: 1-888-627-7079 OR ACCESS
THE HOTEL WEB SITE VIA www.byrdinstitute.org/MCISymposium
Symposium location:
9701 Collins Avenue, Bal Harbour, FL 33154